According to the Independent Sentinel, the Biden regime spent $10.6 billion for the development of this ineffective "drug." Big Pharma firm Pfizer, which manufactures Paxlovid, said back in July that the antiviral medication cut COVID-19 hospitalizations and deaths by 90 percent.
However, recent analyses debunked Pfizer's claim about Paxlovid. One study involving 1,153 patients out of a group of 2,246 COVID-19 patients showed that it only reduced risk by a non-significant 51 percent. Another sub-group analysis, this time involving 721 vaccinated adults with at least one risk factor for progression to severe COVID-19, showed a non-significant relative risk reduction in hospitalization or death.
Even the 79-year-old Biden himself was not spared of Paxlovid's risks. An Aug. 2 memorandum by White House Chief Physician Dr. Kevin O'Connor said the chief executive reported a "rebound infection" on July 30. This prompted a return to isolation, with O'Connor noting that Biden's antigen test on the morning of Aug. 2 returned a positive result.
"[Biden] continues to feel well, though he is experiencing a bit of a return of a loose cough," the physician to the president wrote. Despite this, O'Connor pointed out that Biden doesn't need to undergo another round of Paxlovid treatment after his rebound infection. (Related: White House chief doctor: Biden has "loose cough," continues to be COVID-positive.)
Aside from Biden, White House Chief Medical Advisor Dr. Anthony Fauci also experienced the so-called "rebound infection" from Paxlovid. The 81-year-old infectious disease expert caught COVID-19 in June despite being injected with four doses of the COVID-19 vaccine. He was prescribed a regimen of the antiviral drug and subsequently tested negative after the five-day course.
However, Fauci tested positive again, just four days after finishing the Paxlovid regimen.
Several COVID-19 patients who took the Paxlovid oral treatment have also reported the same rebound infections as the two officials. They tested positive days after finishing a five-day course of the drug, which is a combination of two antiviral drugs – nirmatrelvir and ritonavir.
Given this, several experts spoke out against the antiviral medication and warned that it could cause more harm than good.
Dr. Scott Roberts, an infectious diseases specialist at the Yale School of Medicine, said: "The hypothesis is that the immune system did not have a chance to see the full extent of the virus, since Paxlovid suppressed replication early in the disease."
Dr. Marty Makary, an author and health care expert at Johns Hopkins University, pointed out that the drug was only studied in people with no immune system. He warned: "It has a 50 percent rebound [infection] rate, and prolongs symptoms and length of contagion. On a population level, it drives mutations.
Dr. Robert Malone, the inventor of mRNA vaccine technology, wrote in an article on his Substack page that the word "rebound" to describe infections is a misnomer. He argued that the SARS-CoV-2 virus "has never left Biden's body" and is "still circulating, [albeit] at a fairly undetectable level for a while."
Once a patient begins taking Paxlovid, the drug keeps many of the viruses from reproducing. Some viruses survive and develop a certain resistance to the drug, which causes them to evolve while in the patient's body.
"When a patient is immunosuppressed and doesn't clear the virus, as seems to be happening with Paxlovid, then this evolution has a longer runway to evolve before the virus is cleared by the body. These new strains are then spread throughout the population. Other people can contract the escape mutant resistant lineage and a new variant is born," Malone explained.
"Viruses resistant to Paxlovid are spawned, the virus population explodes, and then the 'rebound' effect is observed – only this time with Paxlovid resistant strains."
Visit DangerousMedicine.com for more stories about the dangers of Paxlovid.
Watch Dr. Pierre Kory, president of the Front Line COVID-19 Critical Care Alliance, discuss the dangers of Paxlovid on "The HighWire with Del Bigtree."
This video is from The HighWire with Del Bigtree channel on Brighteon.com.